<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425188</url>
  </required_header>
  <id_info>
    <org_study_id>CR1079</org_study_id>
    <nct_id>NCT03425188</nct_id>
  </id_info>
  <brief_title>Post Approval Study of the remedē System</brief_title>
  <official_title>Post Approval Study of the remedē System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respicardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respicardia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single arm cohort study to evaluate the long-term safety, long-term
      effectiveness, and survival rate in subjects implanted with the remedē System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Post Approval Study is a multi-center, prospective, single arm cohort study to evaluate
      the long-term safety, long-term effectiveness, and survival rate in subjects implanted with
      the remedē System from the remedē System Pivotal Trial. Only subjects who were implanted and
      actively being followed as part of the remedē System Pivotal Trial are eligible. An
      individual subject's participation is expected to continue to five years post remedē System
      implant.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the survival rate</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Assessment of survival in subjects with moderate to severe central sleep apnea being treated with the remedē System</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate long-term three and five-year device-related Serious Adverse Events (SAEs)</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Assessment of long-term safety via a summary of anticipated or unanticipated device-related SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate long-term three and five-year therapy-related Serious Adverse Events (SAEs)</measure>
    <time_frame>Through 3 and 5 years</time_frame>
    <description>Assessment of the safety of the remedē System by evaluating anticipated or unanticipated therapy-related SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate long-term effectiveness of the remedē System</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>Evaluate the apnea hypopnea index (events/hour) (AHI) using in-home polygram (PG) and at five years using in-lab polysomnogram (PSG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the change in quality of life from baseline to three and five years</measure>
    <time_frame>Baseline, 3 and 5 years</time_frame>
    <description>Quality of life will be evaluated using the Epworth Sleepiness Scale (ESS) at 3 and 5 years post implant of the remedē System compared to baseline.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Central Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>remedē System Subjects</arm_group_label>
    <description>Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Only subjects who were implanted and actively being followed as part of the remedē System
        Pivotal Trial are eligible for this trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who were previously implanted with the remedē System and participated in the
             remedē System Pivotal Trial

          -  In the investigator's opinion, willing and able to comply with all study requirements

          -  Signed Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved
             informed consent (including Health Insurance Portability and Accountability Act
             [HIPAA] authorization in the US)

        Exclusion Criteria:

          -  There are no criteria by which a subject would be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Germany, MD</last_name>
    <role>Study Director</role>
    <affiliation>Respicardia, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Nelson, BSN, MBA</last_name>
    <phone>952-540-4479</phone>
    <email>lnelson@respicardia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Clary</last_name>
    <phone>952-641-4441</phone>
    <email>hclary@respicardia.com</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

